Code Pharma

About Code Pharma

Code Pharma B.V. is a global pharmaceutical entity with its headquarters in the Netherlands and primary research and development activities centered in Israel. The company was founded in 2014 by Zyon Ayni, who currently serves as the Chief Executive Officer. Mr. Ayni possesses extensive experience in the pharmaceutical industry and established the company with the vision of developing novel medical solutions.

The company's strategic focus is on the development of cost-effective treatments for infectious and oncological diseases, leveraging novel peptides. Code Pharma's business model revolves around the entire pharmaceutical lifecycle, from research and development and clinical trials to manufacturing and commercialization. The company aims to make its treatments accessible to a broad demographic, irrespective of income or status. The core of its operations involves bringing together professionals with expertise in peptides, cell cultures, clinical development, and chemistry manufacturing.

Code Pharma's pipeline includes two primary drug candidates: Gammora® and Codivir. Gammora®, originally discovered at the Hebrew University in Israel, is a synthetic peptide being developed as a potential treatment for HIV. Unlike existing treatments that target the virus itself, Gammora® is designed to eliminate HIV-infected cells by inducing self-destruction (apoptosis). The company has presented promising results from clinical trials, suggesting a potential for a cure at the cellular level. Codivir, initially developed for HIV, has been repurposed as an antiviral medication for COVID-19. Clinical trials for Codivir have demonstrated a high safety profile and the ability to significantly suppress viral replication. Following positive results, the drug received emergency use approval in several countries.